Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates

NCT01178944 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01178944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01178944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
November 30, 2015
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, esophageal undifferentiated carcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma, recurrent esophageal adenocarcinoma, recurrent esophageal squamous cell carcinoma, recurrent gastric carcinoma, stage iiib esophageal adenocarcinoma, stage iiib esophageal squamous cell carcinoma, stage iiib gastric cancer, stage iiic esophageal adenocarcinoma, stage iiic esophageal squamous cell carcinoma, stage iiic gastric cancer, stage iv esophageal adenocarcinoma, stage iv esophageal squamous cell carcinoma, stage iv gastric cancer, undifferentiated gastric carcinoma